Amara Therapeutics offers a CE‑marked digital therapeutic, RiSolve®, that delivers evidence‑based behavioural therapy for women with urinary incontinence and overactive bladder via a smartphone app. The platform combines clinician‑designed pelvic‑floor exercises, bladder‑training, and lifestyle coaching with remote support from health professionals, providing a non‑pharmacologic, scalable treatment that can be accessed anytime, anywhere.
Funding
$1.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Women with urinary incontinence face limited access to effective care because traditional treatment pathways rely on scarce specialists, under‑trained primary providers, and in‑person visits that many find embarrassing or inconvenient. This results in a large proportion of sufferers remaining untreated, leading to reduced quality of life, mental health impacts, and high societal costs.
Solution
Amara Therapeutics delivers a digital behavioural therapy platform, RiSolve®, that provides evidence‑based treatment for overactive bladder directly to patients’ smartphones. The CE‑marked solution replaces medication with a structured, clinician‑designed program that guides users through pelvic‑floor exercises, bladder‑training techniques, and lifestyle coaching. Clinical trials across multiple sites have demonstrated improvements in symptoms and quality of life. By combining the digital app with remote support from qualified health professionals, Amara creates a scalable care pathway that can reach women regardless of location, schedule, or ability to pay. The platform adheres to clinical guidelines and integrates data collection for ongoing outcome monitoring.
Target Audience
Primary customers are women experiencing urinary incontinence or overactive bladder who seek convenient, evidence‑based treatment, as well as healthcare providers and insurers looking to offer non‑drug therapeutic options.
Features
- CE‑marked digital therapeutic (RiSolve®) delivering a structured behavioural program for overactive bladder
- Smartphone‑based delivery enables anytime, anywhere access without the need for clinic visits
- Clinically validated through multisite trials showing symptom reduction and quality‑of‑life gains
- Non‑pharmacologic treatment that serves as an alternative to medication
- Remote monitoring and support from experienced health professionals to ensure adherence and personalize care
- Data collection compliant with regulatory standards for continuous outcome tracking